OBJECTIVES: To describe short term outcomes and hernia rates in patients after laparoendoscopic single-site (LESS) in a gynecologic oncology practice.
MATERIALS AND METHODS:
A retrospective, single institution study was performed for patients who underwent LESS from 2007-2015. Univariate analysis was performed with chi-square tests and t-tests; Kaplan-Meier and Cox proportional hazards determined time to hernia development. RESULTS: Eight hundred ninety-eight patients underwent 908 surgeries. The mean age and BMI were 55.7 years and 29.6 kg/m 2 , respectively. The majority were white (87.9%) and ASA class II/III (95.5%). A total of 36.9% had adnexal masses, 37.3% had endometrial hyperplasia/cancer, 5.4% had ovarian/fallopian tube/peritoneal cancer, 4.4% had cervical dysplasia/cancer, and 28% had risk reduction surgery for genetic syndromes (14.1%) or breast cancer (13.9%). Most women (62.7%) underwent hysterectomy, right and left salpingectomy (86.1% and 86.0%, respectively) and right and left oophorectomy (82.2% and 80.3%, respectively). Rate of adverse outcomes within 30 days, including reoperation (0.1%), intraoperative injury (1.4%), ICU admission (0.4%), VTE (0.3%), and blood transfusion were low (0.8%). In this large cohort of patients undergoing LESS, the incidence of short-term adverse outcomes is low. While the rate of incisional hernia was 5.5%, incidence reached 12.3% at three years in high-risk groups. Previous studies with short follow up duration have likely underestimated the risk of hernia, especially in patients with significant comorbidities.
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Gynecologic Surgery, Mayo Clinic Arizona, Phoenix, AZ OBJECTIVES: Vaginal hysterectomy is the recommended approach for patients with benign pathology. When compared to hysterectomies performed via alternative routes, the vaginal approach is associated with decreased perioperative complications, length of hospitalization, and healthcare costs. Increase in uterine size is commonly cited as a relative contraindication to vaginal hysterectomy. The primary objective of this study was to determine the effect of uterine weight on perioperative outcomes among patients undergoing total vaginal hysterectomy. MATERIALS AND METHODS: Consecutive patients undergoing total vaginal hysterectomy between January 1, 2009 and August 31, 2014 were evaluated retrospectively. The primary outcomes were complication and readmission rates based on uterine weight while secondary outcomes included perioperative data. RESULTS: A total of 743 women met study inclusion criteria and underwent vaginal hysterectomy. The uterus weighed 150 g in 489 patients (65.81%), 150-250 g in 119 patients (16.02%), 250-500 g in 74 patients (9.96%), !500 g in 55 patients (7.40%), and was unavailable for 6 patients (0.81%). Significant differences were observed in mean estimated blood loss ( 150 g, 135.3 mL; 150-250 g, 132.0 mL; 250-500 g, 166.1 mL; !500 g, 460.6 mL; p < 0.0001) and operative time ( 150 g, 100.01 min; 150-250 g, 89.24 min; 250-500 g, 90.53 min; !500 g, 115.58 min; p < 0.0001). Conversion to laparotomy was required in 6 patients (0.13%) ( 150 g n ¼ 3, 0.6%; !500 g n ¼ 3, 5.5%; p ¼ 0.0093). Complications were reported in 20 patients (2.69%) and included excessive bleeding (n ¼ 5; 250-500 g n ¼ 2, 2.7%; !500 g n ¼ 3, 5.5%), cystotomy (n ¼ 9; 150 g n ¼ 5, 1.0%; 150-250 g n ¼ 2, 1.7%; !500 g n ¼ 2, 3.6%), proctotomy (n ¼ 2; 150 g n ¼ 2, 0.4%), ureteral injury (n ¼ 2; 150 g n ¼ 2, 0.4%), and unplanned return to the operating room (n ¼ 2; 150 g n ¼ 1, 0.2%; 250-500 g n ¼ 1, 1.4%; p ¼ 0.0013). Hospital readmission occurred in 25 patients (3.36%; 150 g n ¼ 20, 4.09%; 150-250 g n ¼ 4, 3.36%; !500 g n ¼ 1, 1.82%). Emergency department evaluation was required for 49 patients (6.59%; 150 g n ¼ 34, 6.95%; 150-250 g n ¼ 10, 8.40%; 250-500 g n ¼ 3, 4.05%; !500 g n ¼ 2, 3.64%). CONCLUSION: Vaginal hysterectomy for an enlarged uterus is associated with increased perioperative complications and conversion to laparotomy. Hospital readmission and emergency department evaluation most frequently occur in patients with a normal sized uterus.
Megan Wasson: Nothing to disclose; Paul Magtibay: Nothing to disclose; Javier F. Magrina: Nothing to disclose. OBJECTIVES: Ketorolac is an appealing alternative to narcotics in postoperative pain management. However, there is concern for postoperative bleeding with its use. Postoperative bleeding after vaginal reconstructive surgery is a well-established complication and can present acutely secondary to bleeding from the vaginal cuff, vascular pedicles or with deteriorating vital signs indicative of a retroperitoneal hematoma. With conflicting evidence in the literature on postoperative bleeding with ketorolac use, we sought to evaluate and compare the effect of ketorolac on postoperative bleeding and to assess its impact on postoperative pain control. MATERIALS AND METHODS: This is a retrospective cohort study of women who had vaginal reconstructive surgery at Christiana Care Health System between January 1, 2014 and December 31, 2014. Patients were identified through CPT codes for vaginal reconstructive surgeries that required an inpatient stay. Data on preoperative and postoperative hemoglobin levels as well as total narcotic use was collected for each patient. The total narcotic use was then converted to IV hydromorphone using an opioid equivalence conversion. Data analysis was performed using a chi-square test and unpaired t-test to assess the differences in demographics and clinical characteristics of patients who received ketorolac and those who did not receive ketorolac. Multiple regression and linear regression analyses were performed to assess the effect of ketorolac use on hemoglobin and total narcotic use. RESULTS: One hundred twenty-nine vaginal surgery cases were identified in the study period. Of those cases, 54 (41.9%) patients received ketorolac and 75 (58.1%) patients did not receive ketorolac. There was no statistically significant difference in mean narcotic use between the ketorolac group and the no ketorolac group (3.85 mg vs 3.0 mg, p ¼ 0.194). Total ketorolac use was not associated with an increase in estimated blood loss (p ¼ 0.169). Among patients who received ketorolac, there was no significant difference in pre-operative and post-operative hemoglobin when adjusting for estimated blood loss. One patient had a retroperitoneal hematoma and had not received ketorolac. One patient required a blood transfusion and had not received ketorolac. CONCLUSION: This study found that that there was no difference in change in hemoglobin with the use of ketorolac. The total amount of narcotic use was not decreased in patients who received ketorolac postoperatively for additional pain control.
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